IDAC for a Phase III Study in Thrombotic Microangiopathy: Delivering High-Quality Statistical Support Within Budget Constraints

1 minute read

Case Studies

Published: November 12th, 2025

Phastar acted as the Independent Data Analysis Centre (IDAC) for a Phase III trial in thrombotic microangiopathy (TMA) after HSCT. With 13 DMC meetings, ad hoc analyses, and tight budget constraints, our team ensured secure data sharing, expert review, and streamlined workflows—delivering high-quality results while controlling costs.

Download the full case study to explore the approach, outcomes, and lasting impact.

Related articles

Translating Real-World Data into Commercial Success with Outcome Modelling 
Case Studies

Translating Real-World Data into Commercial Success with Outcome Modelling 

July 13th, 2026 1 minute read

Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clini...

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 
Case Studies

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

July 13th, 2026 1 minute read

Biopharma organizations have access to vast amounts of real-world data, but extracting meaningful, actionable insight...

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer
Case Studies

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

July 13th, 2026 1 minute read

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-...